Ralph D'Agostino to Immunotherapy
This is a "connection" page, showing publications Ralph D'Agostino has written about Immunotherapy.
Connection Strength
0.253
-
Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016 Sep 13; 7(37):59860-59876.
Score: 0.120
-
Smith MR, Wang Y, Dixon CB, D'Agostino R, Liu Y, Ruiz J, Oliver G, Miller LD, Topaloglu U, Chan MD, Farris M, Su J, Mileham KF, Li W, Grayson JM, Lycan T, Xing F. Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies. Clin Lung Cancer. 2024 Dec; 25(8):e379-e388.
Score: 0.051
-
Abdulhaleem M, Johnston H, D'Agostino R, Lanier C, LeCompte M, Cramer CK, Ruiz J, Lycan T, Lo HW, Watabe K, O'Neill S, Whitlow C, White JJ, Tatter SB, Laxton AW, Su J, Chan MD. Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases. J Neurooncol. 2022 Mar; 157(1):101-107.
Score: 0.044
-
Routh ED, Pullikuth AK, Jin G, Chifman J, Chou JW, D'Agostino RB, Seino KI, Wada H, Print CG, Zhang W, Lu Y, Miller LD. Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Front Immunol. 2020; 11:57.
Score: 0.038